Kyverna Therapeutics, Inc. — Form 8-K
Filed September 24, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Kyverna announced positive one-year topline data from KYSA-8 (26 SPS patients) showing sustained 49% median improvement in timed 25-foot walk, 95% maintained benefit, 92% remained off chronic immunotherapies, with no high-grade CRS/ICANS/IEC-HS. KYSA-6 Phase 2 (7 gMG patients) showed durable responses sustained to 1.5 years, 100% off immunosuppressants at 24 weeks, 86% off at last follow-up. Rolling BLA submission on track for Q4 2026; Phase 3 enrollment expected complete mid-2027.
Why this rating
Late-stage clinical milestone—positive durability data de-risks regulatory approval path for lead program; BLA filing Q4 2026 imminent. Highly significant relative to $64.5M market cap and pre-revenue biotech profile. Addresses largest unmet need (SPS: zero approved therapies); first-in-class CAR T for autoimmune disease. Near-term binary: regulatory approval probability materially increased.
Price action (we called it positive)
before filing · preread $7.70 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.